Radiopharmaceuticals: all 1,299 studies that test it
Page 7 of 13. Open to participants first (296), then studies with results posted, then the rest; newest registration first within each.
- New Imaging Techniques in the Evaluation of Patients With Ectopic Cushing SyndromeCompletedNCT00001849Phase 2Results posted
- Studies of Elevated Parathyroid ActivityCompletedNCT00001277Phase 2Results posted
- Technetium Tc 99m Sulfur Colloid Injection for Tracing Sentinel Nodes in Breast CancerCompletedNCT07764653Phase 3
- Application and Comparison of [68Ga]Ga-FAPI-04 PET, [18F]FDG PET, and Contrast-Enhanced MRI in Predicting Pathological Response to Neoadjuvant Chemotherapy in Breast Cancer PatientsCompletedNCT07553741Not applicable
- 99mTc-1-thio-D-glucose SPECT/CT Versus 18F-Fluoroethyl-l-tyrosine PET/CT in Brain Tumor ImagingActive, not recruitingNCT07475390Not applicable
- How [14C]-DSP-5336 is Absorbed, Broken Down, and Removed From the Body After a Single Oral Dose in Patients With Advanced Blood CancersCompletedNCT07444268Phase 1
- A Phase 1 Study of 68Ga-R11228 and 177Lu-R11228 in Breast CancerTerminatedNCT07121244Phase 1
- Evaluate the Diagnostic Efficacy, Pharmacokinetics and Safety of 68Ga-DOTATATE Injection PET/CT in NETsActive, not recruitingNCT07119242Phase 3
- Piflufolastat F 18 PET/CT in Patients With Suspected, or at High Risk for Metastatic ccRCCWithdrawnNCT07084909Phase 2/3
- Imaging of Solid Tumors Using DLL3 SPECTWithdrawnNCT07052760Early Phase 1
- PSMA PET Combined With MRI for the Detection of PCaActive, not recruitingNCT07052214Phase 3
- 177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone Marrow Involvement and CytopeniaWithdrawnNCT07025512Phase 2
- 64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate CancerActive, not recruitingNCT06970847Phase 3
- 177LuPSMA in Renal Cell CarcinomaActive, not recruitingNCT06964958Phase 2
- Pilot Study Evaluating Tumor Microenvironment Interaction in Solid Tumor PatientsWithdrawnNCT06922825Early Phase 1
- FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)Active, not recruitingNCT06909825Phase 2
- Comparative Performance of 64Copper [64Cu]-SAR-bis-PSMA vs 68Ga PSMA-11 PET CT for the Detection of Prostate Cancer Recurrence in the Setting of Biochemical Failure Following Radical ProstatectomyCompletedNCT06907641Phase 2
- Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphereActive, not recruitingNCT06900543Phase 3
- Study to Assess [177Lu]Lu-PSMA-R2 (AAA602) and [225Ac]Ac-PSMA-R2 (AAA802) in Participants With PSMA-positive HRLPCWithdrawnNCT06881823Phase 1/2
- A Study of CD8+ T Cell Imaging During Treatment in People With Non-Small Cell Lung CancerCompletedNCT06863233Phase 1
- A Bioequivalence Study Comparing Organic Phosphate (Sodium Glycerophosphate Injection) to Inorganic Phosphate (Sodium Phosphates Injection, USP)CompletedNCT06842121Phase 1
- Test-retest Study With [18F]FBB in Cardiac AmyloidosisCompletedNCT06790394Phase 1
- Study of 68Ga-R10602CompletedNCT06745804Phase 1
- Study of 225Ac-ABD147 to Establish Optimal Dose in Patients With SCLC and LCNEC of the Lung That Previously Received Platinum-based ChemotherapyActive, not recruitingNCT06736418Phase 1
- 64Cu-LLP2A for Imaging Hematologic MalignanciesTerminatedNCT06636175Early Phase 1
- Comparison of Whole Body DWI to FDG PETActive, not recruitingNCT06630845Not applicable
- A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) StudyActive, not recruitingNCT06531499Phase 1
- An Investigational Scan (Ga-68 PSMA-11 PET/CT) for the Detection of Therapy Response in Patients With Metastatic Adenoid Cystic CarcinomaCompletedNCT06521775Phase 2
- A Phase I Study to Assess the Tolerability of 225Ac-DOTATATE in Patients with Refractory and Relapsing Multiple Myeloma Expressing Somatostatin ReceptorsWithdrawnNCT06411301Phase 1
- FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)Active, not recruitingNCT06402331Phase 2
- Pharmacokinetics, Biodistribution, Radiation Dose and Safety Study of 68Ga-NYM005 in PatientsCompletedNCT06389682Phase 1/2
- A Phase 1/2 Study of 177Lu-NYM032 Injection in mCRPCActive, not recruitingNCT06383052Phase 1/2
- NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.Active, not recruitingNCT06379217Phase 1
- A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung CancersTerminatedNCT06376253Phase 1
- Clinical Applications of Integrated PET/MR and PET/CT in the Diagnosis and Treatment of Prostate Cancer.SuspendedNCT06355843Not applicable
- A First-in-Human Study to Learn About How BAY3630942 is Distributed and Processed Inside the Body When Given After BAY3547922 and How Safe it is in People With Liver Cancer or Other Select Solid CancersCompletedNCT06345001Phase 1
- 177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate CancerWithdrawnNCT06329830Phase 1/2
- 177Lu-PSMA (177Lu-PNT2002) in PSMA-Positive Adenoid Cystic CarcinomaTerminatedNCT06322576Phase 2
- Safety and Efficacy of TareSphere in Patients With Unresectable Hepatocellular CarcinomaCompletedNCT06310590Phase 1
- LuCarbo - a Study of 177Lu-PSMA-617 Plus Carboplatin in Metastatic Castrate-resistant Prostate CancerActive, not recruitingNCT06303713Phase 1
- Rose Bengal Electromagnetic Activation With Green Light for Infection Reduction IIActive, not recruitingNCT06271772Phase 3
- FAP PET/CT or PET/MR Production in the Diagnosis, Staging, and Efficacy Assessment of Malignant Tumors ApplicationCompletedNCT06270394Not applicable
- Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate CancerActive, not recruitingNCT06235151Phase 3
- Copper Cu 64 PSMA I&T PET Imaging in Men With Suspected Recurrence of Prostate CancerCompletedNCT06235099Phase 3
- 18F-mFBG Expression in Neural Crest Tumors and Organs Innervated by the Sympathetic Nervous SystemWithdrawnNCT06233903Phase 2
- The Evaluation of the Effectiveness, Safety and Tolerability of Treatment, Using a PSMA-Lu177, in Patients with ACC- an Open, Non-commercial Clinical TrialWithdrawnNCT06199453Phase 2
- 68Ga-DOTA-MGS5 PET/CT in Patients With Advanced Neuroendocrine TumoursCompletedNCT06155994Phase 1/2
- A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid TumoursActive, not recruitingNCT06147037Phase 1
- A Study of 1 8F-FDHT PET/MRIScans in Women With Breast CancerWithdrawnNCT06145399Early Phase 1
- [68Ga]Ga-PentixaFor-PET Imaging for Staging of Marginal Zone LymphomaTerminatedNCT06125028Phase 3
- Using Novel Imaging to More Safely Treat Neuroendocrine TumorsCompletedNCT06122610Phase 1
- Radioligand Therapy After PSMA PET Guided External Beam Radiotherapy for Treating Post-Prostatectomy Patients With Biochemically Recurrent Prostate CancerActive, not recruitingNCT06105918Phase 1
- Gallium (68Ga) Edotreotide PET/CT for Imaging Patients With Gastrointestinal Pancreatic Neuroendocrine TumorsCompletedNCT06091748Phase 3
- PYLARIFY® PET/CT or PET/MRI in Men With Favorable Intermediate Risk (FIR) Prostate CancerActive, not recruitingNCT06074510Phase 4
- Phase I/II Study Evaluating PSMA Targeted Radionuclide Therapy in Adult Patients With Metastatic Clear Cell Renal CancerCompletedNCT06059014Phase 1/2
- A Dose Finding Study to Treat Bone Tumor(s)TerminatedNCT06008483Phase 1
- Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal FunctionActive, not recruitingNCT06004661Phase 2
- Phase 1 Study of 68Ga-R8760TerminatedNCT05999292Phase 1
- A Head-to-head Comparison of [68Ga]Ga-FAPI and [68Ga]Ga-TATE PET/CT in Patients With Nasopharyngeal Carcinoma: a Single-center, Prospective StudyCompletedNCT05990998Phase 1/2
- Phase I Clinical Trial of 68Ga-NOTA-SNA002CompletedNCT05989997Phase 1
- Comparison of Adjuvant Treatment With 177Lu-DOTATATE to Best Supportive Care in Patients After Resection of Neuroendocrine Liver MetastasesTerminatedNCT05987176Phase 2
- Phase I/II Study of [225Ac]Ac-PSMA-R2 in PSMA-positive Prostate Cancer, With/Without Prior 177Lu-PSMA RLTActive, not recruitingNCT05983198Phase 1
- A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors.TerminatedNCT05977322Phase 1
- A Microdose Study of TTX-MC138-NODAGA-Cu64 in Subjects With Advanced Solid TumorsCompletedNCT05908773Early Phase 1
- [68Ga]Ga-FAPI-46 PET/CT in Ovarian CancerTerminatedNCT05903807Phase 2
- [68Ga]Ga-FAPI PET/CT in Gastric and Gastroesophageal Junctional CancerCompletedNCT05898854Phase 2
- Imaging Inflammation With Alcohol Use Disorder: an [18F]NOS StudyActive, not recruitingNCT05885594Early Phase 1
- 18F-FAPI PET Imaging in Pancreatic AdenocarcinomaCompletedNCT05884463Not applicable
- Study Using Hyperpolarized 13C-Pyruvate Magnetic Resonance Spectroscopic Imaging in Patients With Pancreatic Cysts Undergoing Surgical ResectionSuspendedNCT05873699Phase 1
- Radiometabolic Therapy With 177Lu PSMA in PSMA PET/CT Positive Advanced/Metastatic Tumours:Active, not recruitingNCT05867615Phase 2
- Early Assessment of Ovarian Cancer Aggressiveness by Metabolic ImagingSuspendedNCT05866679Phase 1
- Evaluation of 89Zr-TLX250 PET/CT in Chinese Patients With Indeterminate Renal Masses or Suspected Recurrent Renal Clear Cell CarcinomaCompletedNCT05861778Phase 1
- A Study of [14C]GB491 in Male Healthy SubjectsCompletedNCT05860582Phase 1
- Hyperpolarized Carbon-13 Alpha-ketoglutarate Imaging in IDH Mutant GliomaCompletedNCT05851378Early Phase 1
- PET/MR for Prostate Cancer Restaging: a Phase II Prospective Monocentric StudyCompletedNCT05806853Phase 2
- Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid TumorsActive, not recruitingNCT05799274Phase 1
- Ga-68-PSMA-11 in Men With Prostate CancerTerminatedNCT05744115Phase 3
- PET Imaging Using 64Cu-Tz-SarAr and hu5B1-TCO in People With Pancreatic, Colorectal, Bladder Cancer or Cancers With Elevated CA19.9WithdrawnNCT05737615Phase 1
- A Small-molecule Carbonic Anhydrase IX Targeting PET Tracer in Clear Cell Renal Cell CarcinomaCompletedNCT05728515Early Phase 1
- 64Cu-DOTA Pembrolizumab for Imaging Metastatic Solid Tumors in Patients Receiving Stereotactic Body RadiationWithdrawnNCT05728372Early Phase 1
- Evaluating Fluciclovine PET in Patients With Biochemical Recurrence of Prostate Cancer and a Negative PSMA PETActive, not recruitingNCT05722925Phase 4
- 18F-rhPSMA-7.3 PET/MRI in Prostate Cancer Active Surveillance: a Pilot StudyWithdrawnNCT05707182Early Phase 1
- Yttrium-90 Carbon Microspheres in Patients With Unresectable Colorectal Liver MetastasesStatus unknownNCT05692037Phase 1/2
- Tracer Targeting FAP PET Imaging in PatientsStatus unknownNCT05691894Early Phase 1
- FAPI-PET/CT in Psoriatic ArthritisStatus unknownNCT05686876Early Phase 1
- 68Ga-labeled NY104 PET Imaging in PatientsStatus unknownNCT05638256Early Phase 1
- 64Cu-SAR-BBN and 67CU SAR-BBN for Identification and Treatment of Gastrin Releasing Peptide Receptor (GRPR)-Expressing Metastatic Castrate Resistant Prostate Cancer in Patients Who Are Ineligible for Therapy With 177Lu-PSMA-617 (COMBAT)TerminatedNCT05633160Phase 1/2
- 68Ga-P15-041 and 68Ga-PSMA-11 PET/CT Imaging in the Same Group of Prostate Bone MetastasisStatus unknownNCT05627778Phase 1/2
- 99mTc-MIRC213 SPECT/CT for the Detection of HER2-positive Breast CancerStatus unknownNCT05622240Early Phase 1
- Prospective Comparative Study for Patients With Biochemical Recurrence Prostate Cancer Detecting by 18F-JK-PSMA-7Active, not recruitingNCT05622162Phase 3
- Diagnostic Performance and Safety of 18F-NaF-PET/CT in Bone Metastases Compared With 99mTc⁃MDP-BS±SPECTCompletedNCT05614518Phase 3
- Copper-64 SAR Bombesin in PSMA Negative Prostate Cancer (BOP)CompletedNCT05613842Phase 2
- Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGGActive, not recruitingNCT05610891Phase 1
- Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLCActive, not recruitingNCT05595460Phase 1
- [Lu-177]Ludotadipep in Castration-resistant Prostate Cancer(CRPC): Investigation of Drug and Application_2Active, not recruitingNCT05579184Phase 2
- Prostate MRI and Pylarify PSMA PET/CTWithdrawnNCT05568537Phase 4
- F-Tryptophan PET/CT in Human CancersCompletedNCT05556473Phase 1
- [18F]APN-1607 PET in Subjects With AD Compared to HCCompletedNCT05542953Phase 3
- A Bridging Study on Efficacy and Safety of [18F]Florbetaben PET for Diagnosis of Alzheimer Disease Subjects in Chinese PopulationCompletedNCT05527288Not applicable
- Biomarker Identification of Radionuclide Therapy-induced Radiation ResponsesStatus unknownNCT05513469Not applicable